Paroxetine Mesylate Patent Expiration
Paroxetine Mesylate is Used for managing moderate to severe vasomotor symptoms associated with menopause. It was first introduced by Sebela Ireland Ltd
Paroxetine Mesylate Patents
Given below is the list of patents protecting Paroxetine Mesylate, along with the drug name that holds that patent and the company name owning that drug.
Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
---|---|---|---|---|
Brisdelle | US8658663 | Method of treating thermoregulatory disfunction with paroxetine | Apr 06, 2029 | Legacy Pharma |
Brisdelle | US8946251 | Method of treating thermoregulatory dysfunction with paroxetine | Aug 04, 2026 | Legacy Pharma |
Brisdelle | US9393237 | Method of treating thermoregulatory dysfunction with paroxetine | Aug 04, 2026 | Legacy Pharma |
Brisdelle | US7598271 | Crystalline paroxetine methane sulfonate |
May 04, 2025
(Expired) | Legacy Pharma |
Pexeva | US7598271 | Crystalline paroxetine methane sulfonate |
May 04, 2025
(Expired) | Sebela Ireland Ltd |
Brisdelle | US5874447 | 4-Phenylpiperidine compounds for treating depression |
Jun 10, 2017
(Expired) | Legacy Pharma |
Pexeva | US5874447 | 4-Phenylpiperidine compounds for treating depression |
Jun 10, 2017
(Expired) | Sebela Ireland Ltd |
Paroxetine Mesylate's Family Patents

Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List